STATEMENT: SK pharmteco doubles its viral vector production capacity in Europe

SEOUL, South Korea, June 23, 2023 /PRNewswire/ -- SK pharmteco, SK Inc.

STATEMENT: SK pharmteco doubles its viral vector production capacity in Europe

SEOUL, South Korea, June 23, 2023 /PRNewswire/ -- SK pharmteco, SK Inc.'s pharmaceutical contract development and manufacturing organization (CDMO), has successfully completed its second therapeutic manufacturing facility cellular and genetic (C

SK pharmteco announced on June 22 that Yposkesi, its manufacturing subsidiary of commercial viral vectors for C

Yposkesi's second bioproduction center is located on its Genopole campus, the largest biotechnology center in France. This is a 5,000 m2 facility designed in accordance with current US and European Good Manufacturing Practice (GMP) guidelines. Along with the first biomanufacturing facility, also located on the Genopole campus, Yposkesi now has one of the largest biomanufacturing facilities in C

The new center is specialized in the bioproduction of adeno-associated viruses (AAV) and lentiviral vectors (LV), the most widely used viral vectors in the field of cell and gene therapies, ranging from clinical to commercial applications.

Yposkesi is part of a small group of global CDMOs with decades of experience and knowledge in bioprocessing. It is one of the few in Europe that operates two bioproduction platforms for the most widely used viral vectors: adeno-associated virus (AAV) and lentiviral vectors (LV). It has more experience than most companies in the production of viral vectors on an industrial scale.

With multi-customer commitments already secured for the second facility, the company is gearing up for mass production in 2024. According to research firm MarketsandMarkets, the global market for viral vectors, estimated at $5.5 billion (7 .5 trillion KRW) in 2023 and reaching $12.8 billion (16.5 trillion KRW) in 2028, increase with a CAGR of approximately 18%.

Yposkesi is poised to strengthen its global presence due to the increasing demand for viral vectors and few cGMP compliant facilities for large scale production.

In addition, Yposkesi is rapidly expanding its presence in the cancer and immune cell therapy market with the introduction of LentiSure™, a CAR T cell platform designed to optimize higher yields. The facilities are designed with six clean rooms USP (Upstream Process) and two DSP (Downstream Process). This more than triples Yposkesi's bioreactor capacity from 2,000 to 7,000 litres, and reduces project completion times from 18 to 12 months. It has filling and finishing capacities with semi-automated rooms for a total of 12,000 vials per year.

Lentivirus, an important viral vector used in gene therapy and cell-based cancer immune drugs, has experienced increased demand, driven by the expanding market for CAR-T* cell therapy. Leveraging its high-throughput cell culture/harvest capabilities and cost competitiveness, Yposkesi has succeeded in ensuring exceptional quality and on-time delivery of lentiviral vectors.

"It is a great pleasure and pride to inaugurate Yposkesi's new viral vector manufacturing facility today," said Alain Lamproye, Yposkesi's CEO. "This twin plant allows us to keep pace with demand by producing larger quantities of C products.

"We look forward to Yposkesi becoming one of the world's leading cell and gene therapy contract development and manufacturing organizations (CDMOs) through the synergy achieved with the Center for Breakthrough Medicines (CBM), a cell and gene therapy CDMO." based in the United States and a subsidiary of SK pharmteco," said Yeontae Kim, director of the Bioinvestment Center of SK Inc.

In 2019, SK Inc. created SK pharmteco, a globally integrated pharmaceutical contract development and manufacturing organization (CDMO). SK pharmteco operates seven production facilities and five R D centers strategically located in the United States, Europe and Korea. As a subsidiary of SK Inc, SK pharmteco expanded its presence in the rapidly growing biopharmaceutical industry through the acquisition of Yposkesi in 2021, thereby entering the cell and gene therapy market. In addition, in 2022, SK pharmteco became the second largest shareholder in the Center for Breakthrough Medicines, a leading US cell and gene therapy CDMO, securing state-of-the-art production facilities for cell and gene therapy in both Europe as in the United States.

About Yposkesi

Yposkesi, a SK pharmteco company, is one of the largest CDMOs in Europe for the manufacture of viral vectors in cell and gene therapies (C

Yposkesi employs around 200 people and is headquartered at the Campus Genopole in Evry-Courcouronnes (south of Paris), France.

About SK pharmteco

Headquartered in Rancho Cordova, California, SK pharmteco is a global CDMO and a subsidiary of SK Inc., the strategic investment company of SK Group, the second largest conglomerate in South Korea. SK pharmteco was established in 2019 by consolidating highly complementary CDMO business operations. SK pharmteco has established a well-balanced business portfolio by engaging in small molecule and cell and gene therapy to capture both robust and exponential growth in each market. Most recently, SK pharmteco became the second largest shareholder in the Center for Breakthrough Medicines through its investment in March 2022. Today, SK pharmteco has seven manufacturing sites in the United States, Europe and South Korea, as well as from five R&D centers.

Photo -

Photo -

Logo -

View original content: